Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Options Coach’s Substack by Taylor Selden. In this ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

The saga began early last year when Regeneron filed a lawsuit accusing Amgen of infringing a key patent on its best-selling Eylea injectable drug, which is used to combat such eye diseases as wet ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using patents to thwart competition.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to thwart competition ...

You successfully represented Regeneron Pharmaceuticals Inc. in Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals, Inc., in which the US District Court for the Northern District of West Virginia ...

Key matters: Formycon and another v Regeneron Pharmaceuticals Pinsent Masons represents Formycon and Klinge Biopharma in litigation with Regeneron over the clients’ biosimilar version of aflibercept.

Regeneron has asserted the ’865 patent in BPCIA litigations against Mylan, Samsung Bioepis, Celltrion, Formycon, and Amgen.